Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Nathan Unger, PharmD, AAHIVP

Gilead Sciences

Disclosure(s): Gilead Sciences: Employee, Stocks/Bonds

Poster(s):

1251 - 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET